曲妥珠单抗
医学
癌症
癌症研究
癌变
乳腺癌
肺癌
拉帕蒂尼
背景(考古学)
生物标志物
肿瘤科
内科学
生物
遗传学
古生物学
作者
Semir Vranić,Zoran Gatalica
标识
DOI:10.17305/bjbms.2020.4908
摘要
Functional activation of human epidermal growth factor receptor 2 (HER2) has been shown to strongly promote carcinogenesis, leading to the investigation of HER2-directed agents in cancers with HER2 genomic alterations. This has been best documented in the context of HER2 gene amplification in breast and gastric/gastroesophageal junction carcinomas for which several HER2-directed agents are available and have become a part of standard treatment regimens. Somatic HER2 gene mutations have been recently described at low frequency in a variety of human cancers and have emerged as a novel predictive biomarker for HER2-directed therapies. Preclinical data also indicate that activating HER2 mutations are potent oncogenic drivers in a manner that is analogous to HER2 amplification. HER2 mutations may clinically confer sensitivity to HER2-directed agents as recently shown in a phase II clinical trial with antibody-drug conjugate against HER2 trastuzumab deruxtecan in patients with non-squamous non-small cell lung carcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI